drugset
drugset / Trial / NCT02155543

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

NCT02155543 ↗

Phase 1 Completed 51 enrolled Allergan
RandomizedSingle-groupDouble-blindBasic science

Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of AGN-223575 in healthy subjects.

Timeline

Start
2014-05
Primary completion
2014-12
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN-223575 Unknown — —

Indications

No indication recorded.